![](/img/cover-not-exists.png)
Impact of Subsequent Therapies on Outcome of the FIRE-3/AIO KRK0306 Trial: First-Line Therapy With FOLFIRI Plus Cetuximab or Bevacizumab in Patients With KRAS Wild-Type Tumors in Metastatic Colorectal Cancer
Modest, D. P., Stintzing, S., von Weikersthal, L. F., Decker, T., Kiani, A., Vehling-Kaiser, U., Al-Batran, S.-E., Heintges, T., Lerchenmuller, C., Kahl, C., Seipelt, G., Kullmann, F., Stauch, M., SchLanguage:
english
Journal:
Journal of Clinical Oncology
DOI:
10.1200/jco.2015.61.2887
Date:
August, 2015
File:
PDF, 291 KB
english, 2015